Holen Sie sich die Stockscreener-App
4.29
2.39%
0.10
Handel nachbörslich:
4.28
-0.010
-0.23%
Schlusskurs vom Vortag:
$4.19
Offen:
$4.23
24-Stunden-Volumen:
2.28M
Relative Volume:
0.49
Marktkapitalisierung:
$849.87M
Einnahmen:
$191.45M
Nettoeinkommen (Verlust:
$160.72M
KGV:
5.2158
EPS:
0.8225
Netto-Cashflow:
$-34.44M
1W Leistung:
+2.63%
1M Leistung:
-15.22%
6M Leistung:
-4.24%
1J Leistung:
-4.03%
1-Tages-Spanne:
$4.215
$4.30
1-Wochen-Bereich:
$4.05
$4.30
52-Wochen-Spanne:
$3.50
$5.45
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.29 | 849.87M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Form 13D/A Arbutus Biopharma Corp For: 5 October By Investing.com - Investing.com UK
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results. - Stock Titan
About 23% of Arbutus shares are being bought back for $230 million. - Stock Titan
Arbutus gains on plans to buy back 46M shares in tender offer - TradingView
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewswire
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq:QTTB)Stock Analysis - simplywall.st
Arbutus Biopharma Stock Price Forecast. Should You Buy ABUS? - StockInvest.us
ABUS Stock Price, Quote & Chart - ChartMill
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS) - Stock Titan
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma (ABUS) Edges Up to $5.12, Stuck Between $4.86 Support and $5.38 ResistanceVolatility Term Structure - careplusvn.com
Arbutus Biopharma Corp (ABUS) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Quantum BioPharma Ltd Peer Comparison – Compare with Others - Value Research
Cronos Group Inc. Common Share (CRON) Peer Comparison – Compare with Others - Value Research
Acasti Pharma Inc. Class AADR Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share - Yahoo Finance
Arbutus Commences US$230 Million Modified “Dutch - GlobeNewswire
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares - Yahoo Finance
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Arbutus Biopharma Announces $230 Million Modified Dutch Auction Tender Offer for Shares - Kalkine Media
Why is Arbutus Biopharma stock surging today? - Investing.com India
Why is Arbutus Biopharma stock surging today? - Investing.com
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Yahoo Finance
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Biopharma Corporation announces an Equity Buyback for $230 million worth of its shares. - marketscreener.com
Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds - Bloomberg.com
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - TradingView
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - stocktitan.net
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arbutus Biopharma Corp-Aktie (ABUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nguyen Tuan | Chief Financial Officer |
Sep 18 '26 |
Option Exercise |
3.57 |
293,100 |
1,047,646 |
366,600 |
| Sawhney Roger | Director |
Sep 18 '26 |
Option Exercise |
3.88 |
131,333 |
509,572 |
131,333 |
| Beardsley Robert A | Director |
Sep 18 '26 |
Option Exercise |
3.82 |
131,333 |
502,218 |
131,333 |
5.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):